[Study Completion] Successful Completion of Phase 1 Trial of New Asthma Drug!
01/09/2019
The investigational drug, Benralizumab, is a novel drug for treating asthma. It was approved in USA, European Union, Japan and Canada. HKU Clinical Trials Centre conducted the phase 1 clinical research of the drug to evaluate the metabolism and safety of the drug using different doses in Chinese population.
Recruitment started in March 2019 and 36 healthy volunteers were selected to join the study. The whole study took 17 weeks and it included screening, 3-day-2-night confinement and follow-up visits. Volunteers were divided into 2 groups to receive injection. The research was completed in August 2019.
Potential New Treatment for Advanced HCC Went Through Successful Phase 1 and Phase 2 Studies
31/07/2019
Potential New Treatment for Advanced HCC Went Through Successful Phase 1 and Phase 2 Studies
31/07/2019
Study Shows New Drugs for Hepatitis C Well-Tolerated in Chinese Participants
24/07/2019
Phase 1 Study Shows Effective Antiviral Response of Novel Drug for Hepatitis B Virus (HBV)
24/07/2019
Phase 1 Study Shows Effective Antiviral Response of Novel Drug for Hepatitis B Virus (HBV)
24/07/2019
Immunotherapy Drug Proven More Effective Than Traditional Sorafenib Treatment for HCC Patients
24/07/2019
Immunotherapy Drug Proven More Effective Than Traditional Sorafenib Treatment for HCC Patients
24/07/2019
Potential New Treatment for Advanced HCC Went Through Successful Phase 1 and Phase 2 Studies
24/07/2019
Potential New Treatment for Advanced HCC Went Through Successful Phase 1 and Phase 2 Studies
24/07/2019
Successful Study on New Drug for Chronic Lymphocytic Leukemia (CLL) Paves Way for Phase 2 Study on Efficacy and Safety of the Selected Dosage
24/07/2019
Successful Study on New Drug for Chronic Lymphocytic Leukemia (CLL) Paves Way for Phase 2 Study on Efficacy and Safety of the Selected Dosage
24/07/2019
[Centre Activity] HKU/QMH Completed NMPA Re-inspection and Received Clinical Trials Accreditation in a Total of 14 Clinical Specialties/Areas
25/06/2019
[Centre Activity] HKU/QMH Completed NMPA Re-inspection and Received Clinical Trials Accreditation in a Total of 14 Clinical Specialties/Areas
25/06/2019
National Medical Products Administration (NMPA, previously called China Food and Drug Administration) visited Queen Mary Hospital on 29th April, 2019 for re-inspection on 14 clinical specialties (including HKU Phase 1 Clinical Trials Centre, cardiology, endocrinology & metabolism, respiratory medicine, hepatobiliary & pancreatic surgery and liver transplantation, obstetrics & gynaecology, haematology & bone marrow transplantation, neurology, nephrology, clinical immunology, orthopaedics & traumatology, gastroenterology & hepatology, oncology and paediatrics & adolescent medicine). The overall inspection result was satisfactory and the said specialties successfully received the continuing accreditation by the NMPA, meaning that the clinical drug trial data from these specialties are acceptable by the NMPA for evaluation of new drug approval applications.
HKU/QMH has been accredited by the NMPA for conducting clinical drug trials in six clinical specialties since 2006. HKU Phase 1 Clinical Trials Centre and seven additional clinical specialties were further accredited in July 2016.
